Table 1.
Description of the components of the quality evaluation instrument (QEI) used to evaluate websites with information on NAFLD (scores range from 0 to 56)
| Defines NAFLD | ||||||||
| Describes NAFLD as term that includes non-alcoholic fatty liver, NASH and non-alcoholic fatty liver associated cirrhosis (1) | ||||||||
| Define significant alcohol intake amount differentiate from alcoholic liver disease (2) | ||||||||
| Epidemiology of NAFLD | ||||||||
| Discusses incidence and prevalence of NAFLD | ||||||||
| Incidence (3) | ||||||||
| Prevalence (4) | ||||||||
| Discusses risk factor of NAFLD | ||||||||
| Obesity (5) | ||||||||
| Diabetes mellitus type II (6) | ||||||||
| Dyslipidemia (7) | ||||||||
| Prevalence (4) | ||||||||
| Metabolic syndrome (8) | ||||||||
| Hypothyroidism (9) | ||||||||
| Polycystic ovarian syndrome (10) | ||||||||
| Sleep apnea (11) | ||||||||
| Discusses natural course of NAFLD | ||||||||
| Total mortality (12) | ||||||||
| Liver related disease progression (13) | ||||||||
| Cardiovascular disease as most common cause of mortality (14) | ||||||||
| Discusses comorbidity of NAFLD | ||||||||
| Cardiovascular disease (15) | ||||||||
| Diabetes mellitus type II (16) | ||||||||
| Diagnosis of NAFLD | ||||||||
| Discusses about when and which test should be performed to diagnosis and screen of NAFLD. | ||||||||
| Discusses about diagnostic method | ||||||||
| History taking and serologic test for rule out other cause (17) | ||||||||
| Blood liver function test (18) | ||||||||
| Abdominal sonography (19) | ||||||||
| Discusses screening indication | ||||||||
| Insulin resistance patient (20) | ||||||||
| Blood test and abdominal sonography (21) | ||||||||
| Discusses comorbidity screening in NAFLD patient | ||||||||
| Metabolic syndrome (22) | ||||||||
| Cardiovascular disease (23) | ||||||||
| Diabetes mellitus type II (24) | ||||||||
| Discusses non-invasive test about NASH and advanced fibrosis | ||||||||
| Radiology method | ||||||||
| Liver ultrasonography (25) | ||||||||
| Computed tomography (26) | ||||||||
| Magnetic resonance image (27) | ||||||||
| Magnetic resonance spectroscopy (28) | ||||||||
| Elastography | ||||||||
| Transient elastography (29) | ||||||||
| Controlled attenuation parameter (30) | ||||||||
| Magnetic resonance elastography (31) | ||||||||
| Biochemical panel | ||||||||
| NAFLD fibrosis score (32) | ||||||||
| Enhanced liver fibrosis panel (33) | ||||||||
| Cytokeratin-18 fragments (34) | ||||||||
| Discusses liver biopsy indication and efficacy with complication | ||||||||
| Indication (35) | ||||||||
| Efficacy (36) | ||||||||
| Complication (37) | ||||||||
| Management of NAFLD | ||||||||
| Discusses treatment modality of NAFLD | ||||||||
| Lifestyle modification: discusses efficacy and method | ||||||||
| Weight reduction (38) | ||||||||
| Diet (39) | ||||||||
| Exercise (40) | ||||||||
| Drug for weight reduction (41) | ||||||||
| Medical treatment: discusses efficacy and complication | ||||||||
| Anti-oxidant | ||||||||
| Vitamin E (42) | ||||||||
| Other anti-oxidant (43) | ||||||||
| Insulin sensitizer | ||||||||
| Thiazolidinediones (44) | ||||||||
| Metformin (45) | ||||||||
| Lipid lower agents | ||||||||
| Statins (46) | ||||||||
| Fibrates (47) | ||||||||
| Omega-3 polyunsaturated fatty acid supplementation (n-3 PUFAs) (48) | ||||||||
| Ezetimibe (49) | ||||||||
| Pentoxifylline (50) | ||||||||
| Ursodeoxycholic acid (UDCA) (51) | ||||||||
| Angiotensin-II receptor blockers (52) | ||||||||
| Investigating others drugs (53) | ||||||||
| Surgical treatment: discusses indication, efficacy, and complication | ||||||||
| Bariatric surgery | ||||||||
| Indication (54) | ||||||||
| Efficacy (55) | ||||||||
| Complication (56) | ||||||||
NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.